A 7-day delay in methylprednisolone administration in patients with optic neuritis due to neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), or double-seronegative optic neuritis (DN-ON) significantly decreases the odds of gaining visual recovery, according to a recently published study in Vision. Optic neuritis can be caused by several diseases, including NMOSD, MS, and DN-ON.…
There are more than 1000 plant species that may have therapeutic relevance in tackling neurodegenerative diseases such as Friedreich ataxia, spinal muscular atrophy, and multiple sclerosis, according to a study published in IBRO Neuroscience Reports. While significant pharmacological progress has been made for certain diseases (such as those involving the cardiopulmonary system), effective therapies tackling…
Using 1 gram rituximab as maintenance therapy for inflammatory neurologic conditions such as neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) appears to be effective maintenance therapy. In contrast, 2 grams seem excessive, according to a recently published study in Multiple Sclerosis and Related Disorders. Several studies have widely established the efficacy of rituximab…
People with primary progressive multiple sclerosis (pwPPMS) have a reduced number of memory and regulatory immune cells compared to healthy controls, according to a study published in Cells. During the study, it was observed that pwPPMS had lower numbers of central memory (CM; CD45RA−CCR7+) T cells expressing CD4+ and CD8+ as well as a reduction…
A deficiency of regulatory T cells (Tregs) may be one of the immunological mechanisms responsible for the damage observed in secondary progressive multiple sclerosis (SPMS), according to a study published in International Immunology. The study found that the percentage of Tregs positive for CD4, CD25, forkhead box protein P3 (FOXP3), and Helios markers (CD4+CD25+FOXP3+Helios+ Tregs)…
A recent study published in Brain has confirmed that primary progressive multiple sclerosis (PPMS) is an antibody-mediated disease with unique clinical and pathological features distinct from other forms of MS. The research conducted by the Tisch MS Research Center of New York has confirmed what the scientific community long suspected: PPMS is pathophysiologically distinct from other forms…
A second patient with nonactive secondary progressive multiple sclerosis (SPMS) showed additional improvements following treatment with foralumab, according to a press release from Tiziana Life Sciences, the developers of the treatment. The patient had already shown clinical improvements in September 2022. “The sustained improvement in EDSS score starting at 6 months and further improving after…
A new study testing the effect of a home-based action observation treatment for arm rehabilitation in multiple sclerosis patients (MS) is now open. The aims of the study are to compare the effects of a home-based virtual reality action observation treatment to a virtual reality landscape observation on the motor performance of the arms, to…
The organelle dysfunction that occurs in neurons of individuals with multiple sclerosis (MS) may not be related to a symptomatic state, according to a study recently published in Neurobiology of Diseases. “Data further our understanding of mechanisms related to experimental autoimmune encephalomyelitis progression and point to very early axonal mitochondrial dysfunction as central to the…
Some metals could directly influence the pathogenesis of multiple sclerosis (MS), according to a study published in the Journal of Proteome. “However, the rapid progression of primary progressive MS from the onset may be driven by a combination of neurotoxicity induced by heavy metals coupled with diminished CNS antioxidative capacity associated with differential intrathecal ascorbate retention…
Please login or register first to view this content.
